127 related articles for article (PubMed ID: 1902868)
41. Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels.
Gürlek A; Bayraktar M; Kirazli S
Diabetes Care; 2000 Jan; 23(1):88-92. PubMed ID: 10857975
[TBL] [Abstract][Full Text] [Related]
42. Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men.
Glueck CJ; Glueck HI; Stroop D; Speirs J; Hamer T; Tracy T
J Lab Clin Med; 1993 Oct; 122(4):412-20. PubMed ID: 8228555
[TBL] [Abstract][Full Text] [Related]
43. The effects of atorvastatin treatment on the fibrinolytic system in dyslipidemic patients.
Orem C; Uydu HA; Yilmaz R; Gökçe M; Baykan M; Eminagaoglu S; Orem A
Jpn Heart J; 2004 Nov; 45(6):977-87. PubMed ID: 15655273
[TBL] [Abstract][Full Text] [Related]
44. Progressive intermittent claudication is associated with impaired fibrinolysis.
Killewich LA; Gardner AW; Macko RF; Hanna DJ; Goldberg AP; Cox DK; Flinn WR
J Vasc Surg; 1998 Apr; 27(4):645-50. PubMed ID: 9576077
[TBL] [Abstract][Full Text] [Related]
45. Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias.
Zitoun D; Bara L; Basdevant A; Samama MM
Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):77-81. PubMed ID: 8548430
[TBL] [Abstract][Full Text] [Related]
46. Tissue-type plasminogen activator, plasminogen activator inhibitor, and histidine-rich glycoproteins in stressed human newborns.
Corrigan JJ; Jeter MA
Pediatrics; 1992 Jan; 89(1):43-6. PubMed ID: 1728019
[TBL] [Abstract][Full Text] [Related]
47. Reduced levels of tissue plasminogen activator and plasminogen activator inhibitor in plasma of patients with familial amyloidotic polyneuropathy.
Olofsson BO; Nilsson TK
Haemostasis; 1990; 20(1):31-6. PubMed ID: 2108913
[TBL] [Abstract][Full Text] [Related]
48. Fibrinolytic response in normal subjects to venous occlusion and DDAVP infusion.
Cugno M; Uziel L; Fabrizi I; Bottasso B; Maggiolini F; Agostoni A
Thromb Res; 1989 Dec; 56(5):625-34. PubMed ID: 2516662
[TBL] [Abstract][Full Text] [Related]
49. Endogenous fibrinolytic system in chronic large-vessel thromboembolic pulmonary hypertension.
Olman MA; Marsh JJ; Lang IM; Moser KM; Binder BR; Schleef RR
Circulation; 1992 Oct; 86(4):1241-8. PubMed ID: 1394930
[TBL] [Abstract][Full Text] [Related]
50. Enhanced levels of tissue-type plasminogen activator in borderline hypertension.
Wall U; Jern C; Bergbrant A; Jern S
Hypertension; 1995 Nov; 26(5):796-800. PubMed ID: 7591020
[TBL] [Abstract][Full Text] [Related]
51. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan.
Makris TK; Stavroulakis G; Papadopoulos DP; Krespi P; Hatzizacharias A; Zilidis A; Tsoukala C; Votteas VE
Drugs Exp Clin Res; 2004; 30(3):125-32. PubMed ID: 15366789
[TBL] [Abstract][Full Text] [Related]
52. The effect of chronic allograft rejection on plasma regulators of fibrinolysis.
Perkowska A; Elhasade A; Durlik M; Placha G; Gałazka Z; Lao M; Gaciong Z
Ann Transplant; 2002; 7(1):44-51. PubMed ID: 12221903
[TBL] [Abstract][Full Text] [Related]
53. The fibrinolytic system is not impaired in older men with hypertension.
DeSouza CA; Dengel DR; Rogers MA; Cox K; Macko RF
Hypertension; 1996 May; 27(5):1053-8. PubMed ID: 8621196
[TBL] [Abstract][Full Text] [Related]
54. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
Chudý P; Kotuličová D; Staško J; Kubisz P
Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
[TBL] [Abstract][Full Text] [Related]
55. Newborn's fibrinolytic mechanism: components and plasmin generation.
Corrigan JJ; Sleeth JJ; Jeter M; Lox CD
Am J Hematol; 1989 Dec; 32(4):273-8. PubMed ID: 2530897
[TBL] [Abstract][Full Text] [Related]
56. Changes in plasminogen activator inhibitor 1 and tissue-type plasminogen activator during exercise in patients with coronary artery disease.
Rydzewski A; Sakata K; Kobayashi A; Yamazaki N; Urano T; Takada Y; Takada A
Haemostasis; 1990; 20(5):305-12. PubMed ID: 2127039
[TBL] [Abstract][Full Text] [Related]
57. Elevated tissue plasminogen activator in patients with screening-detected abdominal aortic aneurysm.
Wanhainen A; Nilsson TK; Bergqvist D; Boman K; Björck M
J Vasc Surg; 2007 Jun; 45(6):1109-13. PubMed ID: 17543671
[TBL] [Abstract][Full Text] [Related]
58. Increased levels of tissue plasminogen activator antigen in essential hypertension. A population-based study in Sweden.
Eliasson M; Jansson JH; Nilsson P; Asplund K
J Hypertens; 1997 Apr; 15(4):349-56. PubMed ID: 9211169
[TBL] [Abstract][Full Text] [Related]
59. Effects of doxazosin and atenolol on atherothrombogenic risk profile in hypertensive middle-aged men.
Andersen P; Seljeflot I; Herzog A; Arnesen H; Hjermann I; Holme I
J Cardiovasc Pharmacol; 1998 May; 31(5):677-83. PubMed ID: 9593066
[TBL] [Abstract][Full Text] [Related]
60. Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction.
Thøgersen AM; Söderberg S; Jansson JH; Dahlén G; Boman K; Nilsson TK; Lindahl B; Weinehall L; Stenlund H; Lundberg V; Johnson O; Ahrén B; Hallmans G
Eur J Cardiovasc Prev Rehabil; 2004 Feb; 11(1):33-40. PubMed ID: 15167204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
